Sigvotatug vedotin
Based on 1 Customer Validation
Sigvotatug vedotin (SGN-B6A; PF-08046047) is an ADC that targets integrin β-6 (ITGB6) via the human IgG1 monoclonal antibody Sigvotatug (HY-P990764) (EC50 = 0.9 nM) and exhibits cytotoxicity against a variety of integrin β-6-positive cancer cells through the tubulin polymerization inhibitor MMAE (HY-15162).
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Antibody:
- Linker-Payload:
-
Drug-to-Antibody Ratio:
4
-
Conjugate Type:
Random Cysteines
- Reinheit : 98.42%
- CAS. Nr.: 2764774-91-4
- Molecular Weight:150000 (average)
-
Speicherung:Shipping with dry ice
-80°C, protect from light
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Protokoll
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
![Br-Val-Ala-NH2-bicyclo[1.1.1]pentane-7-MAD-MDCPT](https://file.medchemexpress.com/product_pic/hy-148820.gif)
Biologische Aktivität
Beschreibung
IC50 & Target
[1]|
ITGB6 |
tubulin |
In Vitro
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:BxPC-3 pancreatic carcinoma cells
-
Concentration:2 μg/mL
-
Incubation Time:30 minutes on ice (preincubation); 4 hours at 37 °C (internalization assessment)
-
Result:Localized as a halo of red staining on the BxPC-3 cell plasma membrane at time 0.
Colocalized with green-stained lysosomes (appearing as orange color in intracellular vesicles) by 4 hours.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:nude mice (female, 5 to 8 weeks old)[1]
-
Dosage:1 mg/kg; 3 mg/kg
-
Administration:i.p.; weekly; 3 doses
-
Result:Showed dose-dependent anti-tumor activity, including the induction of tumor regression.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Product Details
-
Antibody
-
Linker-Payload
-
Drug-to-Antibody Ratio
4
-
Conjugate Type
Random Cysteines
Chemical Information
-
CAS. Nr. 2764774-91-4
-
Appearance Liquid
-
Molecular Weight 150000 (average)
-
Color Colorless to light yellow
-
SMILES
[Sigvotatug vedotin]
-
Synonyms
SGN-B6A; PF-08046047
-
Versand
Shipping with dry ice.
-
Speicherung
-80°C, protect from light
Reinheit & Dokumentation
-
Data Sheet (272 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Sigvotatug vedotin Related Classifications
HY-164957 Related Classifications
Powered by Bioz
Keywords
- Sigvotatug vedotin
- 2764774-91-4
- SGN-B6A
- PF-08046047
- PF08046047
- PF 08046047
- PF-08046047
- Antibody-Drug Conjugates (ADCs)
- Integrin
- Microtubule/Tubulin
- Antibody-Drug Conjugates
- ADC
- integrin alpha-v/beta-6
- monomethyl auristatin E
- non-small cell lung carcinoma
- integrin beta-6-expressing carcinoma cells
- pancreatic carcinoma
- bladder carcinoma
- Detroit 562 cells
- cynomolgus monkeys
- lysosomal pathway
- BxPC-3 cells
- Inhibitor
- inhibitor
- inhibit